| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Women’s Medical and Diagnostic Center and the Climacteric Clinic Inc, Gainesville, Florida; Hill Top Research, Inc, Atlanta, Georgia; and Novo Nordisk Pharmaceuticals, Inc, Princeton, New Jersey.
Address reprint requests to: M. Notelovitz, MD, PhD, Adult Women’s Medicine, 2801 NW 58th Boulevard Gainesville, FL 32605; E-mail: mnotelo{at}aol.com.
OBJECTIVE: To evaluate absorption of estradiol (E2) and compare two low doses of 17 ß-E2 (25 µg and 10 µg) in postmenopausal women with atrophic vaginitis.
METHODS: In a double-masked, randomized, parallel-group study, 58 postmenopausal women were treated with 25 µg or 10 µg of 17 ß-E2 for 12 weeks. We report data for 42 eligible subjects who had serum E2 concentrations below 20 pg/mL at baseline and complete data available at the baseline visit (30 minutes before tablet insertion) and weeks 2 and 12. Serum E2 and FSH concentrations were measured at specified intervals. The area under the curve, maximal concentration, and time to maximal concentration were measured for serum E2 concentrations. Maturation values of vaginal epithelial cells were assessed as indicators of change in vaginal epithelium condition in response to treatment.
RESULTS: After 12 weeks of treatment, the area under the curve, maximal and average over 24-hour E2 concentration were higher in the 25-µg (563 pg · hour/mL, 49 and 23 pg/mL) than in the 10-µg (264 pg · hour/mL, 22 and 11 pg/mL) group. Seventy-four percent in the 25-µg and 96% in the 10-µg groups had low systemic absorption of E2, that is, area under the curve (0–24 hour) less than 500 pg/mL. All but three women who received 25 µg had mean FSH levels below 35 mIU/mL.
CONCLUSION: Treatment with 25 or 10 µg of 17 ß-E2 vaginal tablets resulted in low absorption of estrogen without systemic effects often associated with hormone replacement therapy. After 12 weeks of therapy for atrophic vaginitis, absorption patterns remained consistent, and women did not have accumulations of circulating E2.
This article has been cited by other articles:
|
|
 |
|
  J. Simon, L. Nachtigall, R. Gut, E. Lang, D. F. Archer, and W. Utian Effective Treatment of Vaginal Atrophy With an Ultra-Low-Dose Estradiol Vaginal Tablet Obstet. Gynecol., November 1, 2008; 112(5): 1053 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pitkin, M. Rees, and on behalf of the British Menopause Society Council Urogenital atrophy Menopause Int, September 1, 2008; 14(3): 136 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Wilson, P. M. Coplan, M. A. Wainberg, and S. M. Blower The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics PNAS, July 15, 2008; 105(28): 9835 - 9840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Trinkaus, S. Chin, W. Wolfman, C. Simmons, and M. Clemons Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens? Oncologist, March 1, 2008; 13(3): 222 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bachmann, R. A. Lobo, R. Gut, L. Nachtigall, and M. Notelovitz Efficacy of Low-Dose Estradiol Vaginal Tablets in the Treatment of Atrophic Vaginitis: A Randomized Controlled Trial Obstet. Gynecol., January 1, 2008; 111(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann. Onc., April 1, 2006; 17(4): 584 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genitourinary Tract Changes Obstet. Gynecol., October 1, 2004; 104(4_suppl): 56S - 61S. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
